Solid-Phase Synthesis of l,4-Benzodiazepine-2,5-diones. Library Preparation and Demonstration of Synthesis Generality

Journal of Organic Chemistry

Volumn 62, Issue 5, 1997, Pages 1240-1256

  Boojamra, Constantine G ^a,b   Burow, Kristina M ^a   Thompson, Lorin A ^a   Ellman, Jonathan A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Microcide Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZODIAZEPINE 2,5 DIONE DERIVATIVE; BENZODIAZEPIN 2 ONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; IN VITRO STUDY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 0030932342     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo9622845     Document Type: Article

References (97)

1. Thompson, L. A.; Ellman, J. A. Chem. Rev. 1996, 96, 555-600.
2. Choong, I. C., Ellman, J. A. Annu. Rep. Med. Chem. 1996, 31, 309-318.
3. Terrett, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J. Tetrahedron 1995, 51, 8135-8173.
4. Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gallop, M. A. J. Med. Chem. 1994, 37, 1385-1401.
5. Früchtel, J. S.; Jung, G. Angew. Chem., Int. Ed. Engl. 1996, 35, 17-42.
6. Ariens, E. J.; Beld, A. J.; Rodrigues de Miranda, J. F.; Simonis, A. M. In The Receptors: A Comprehensive Treaty; O'Brien, R. D., Ed.; Plenum: New York, 1979; Vol. 1; pp 33-41.
7. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
8. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
9. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
10. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
11. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
12. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
13. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
14. Selected 1,4-benzodiazepine therapeutic agents or promising candidates: (a) Anxiolytics, hypnotics, and antiepileptics: Sternbach, L. H. J. Med. Chem. 1979, 22, 1-7. (b) Cholecystokinin antagonists: Evans, B. E. et al. J. Med. Chem. 1988, 31, 2235-2246. (c) Opioid receptor antagonist: Romer, D. et al. Nature 1982, 298, 759-760. (d) HIV Tat antagonist: Hsu, M.-C. et al. Science 1991, 254, 1799-1802. (e) HIV reverse transcriptase inhibitor: Pauwels, R. et al. Nature 1990, 343, 470-474. (f) Platelet aggregating factor antagonist: Miyazawa, S. et al. Chem. Pharm. Bull. 1992, 40(2), 521-523 (thienodiazepine derivative), (g) Antipsychotics: Liégeois, J.-F. F.; Bruhwyler, J.; Damas, J.; Nguyen, T. P.; Chleide, E. M. G.; Mercier, M. G. A.; Register, F. A.; Delarge, J. E. J. Med. Chem. 1993, 36, 2107-2114. (h) Oxytocin antagonist: MDDR MDL Drug Data Report data base. MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA.
15. Webb, R. R.; Barker, P. R.; Baier, M.; Reynolds, M. E.; Robarge, K. D.; Blackburn, B. K.; Tichler, M. H.; Weese, K. J. Tetrahedron Lett. 1994, 35, 2113-2116.
16. Blackburn, B. K.; Lee, A.; Baier, M Atropisomeric GPIIbIIIa antagonists. Presented at the 209th National Meeting of the American Chemical Society, Anaheim, CA; American Chemical Society: Washington, DC, 1995; ORGN 280.
17. McDowell, R. S.; Blackburn, B. K.; Gadek, T. R.; McGee, L. R.; Rawson, T.; Reynolds, M.; Robarge, K. D.; Somers, T. C.; Thorsett, E. D.; Tischler, M.; Webb, R. R.; Venuti, M. C. J. Am. Ckem. Soc. 1994, 116, 5077-5083.
18. McDowell, R. S.; Gadek, T. R.; Barker, P. L.; Burdick, D. J.; Chan, K. S.; Quan, C. L.; Skelton, N.; Strumble, M.; Thorsett, E. D.; Tischler, M.; Tom, J. Y. K.; Webb, T. R.; Burnier, J. J. Am. Chem. Soc. 1994, 116, 5069-5076.
19. Ishikura, M.; Mori, M.; Terashima, M.; Ban, Y. J. Chem. Soc., Chem. Commun. 1982, 741-742.
20. Mori, M.; Uozumi, Y.; Kimura, M.; Ban, Y. Tetrahedron 1988, 42, 3793-3806.
21. Reed, J. N.; Snieckus, V. Tetrahedron Lett. 1984, 25, 5505.
22. Kaneko, T.; Wong, H.; Doyle, T. W. Tetrahedron Lett. 1983, 24, 5165-5168.
23. Stevens, R. V.; Cory, R. M.; Rossen, S. J. Chem. Soc., Chem. Commun. 1975, 742.
24. Confalone, P. N.; Huie, E. M.; Ko, S. S.; Cole, G. M. J. Org. Chem. 1988, 53, 482-487.
25. Peña, M. R.; Stille, J. K. Tetrahedron Lett. 1987, 28, 6573-6576.
26. Peña, M. R.; Stille, J. K. J. Am. Chem. Soc. 1989, 111, 5417-5424.
27. Hunkeler, W. Chimia 1993, 47, 141-147.
28. Suzdak, P. D.; Glowa, J. R.; Crawley, J. N.; Schwartz, R. D.; Skolnick, P.; Paul, S. M. Science 1986, 234, 1243-1247.
29. Pole, P.; Richards, J. G. Br. J. Pharmacol. 1985, 86, 465P.
30. Malminiemi, O.; Korpi, E. R. Eur. J. Pharmacol. 1989, 169, 53-60.
31. Bonetti, E. P.; Burkard, W. P.; Gabl, M.; Mohler, H.; Richards, J. G. Br. J. Pharmacol. 1985, 86, 463P.
32. Karp, G. M. J. Org. Chem. 1995, 60, 5814-5819.
33. White, J. D.; Haefliger, W. E.; Dimsdale, M. J. Tetrahedron 1970, 26, 233-242.
34. Smith, H.; Wegfahrt, P.; Rapoport, H. J. Am. Chem. Soc. 1968, 90, 1668-1669.
35. Richter, H.; Winter, K.; Kousy, S. E.; Luckner, M. Pharmazie 1974, 29, 506-510.
36. Martin, P. K.; Rapoport, H.; Smith, H. W.; Wong, J. L. J. Org. Chem. 1969, 34, 1359-1363.
37. Bunin, B. A.; Plunkett, M. J.; Ellman, J. A. Methods Enzymol. 1996, 267, 448-465.
38. Bunin, B. A.; Plunkett, M. J.; Ellman, J. A. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4708-4712.
39. Bunin, B. A.; Ellman, J. A. J. Am. Chem. Soc. 1992, 114, 10997-10998.
40. DeWitt, S. H.; Kiely, J. S.; Stankovic, C. J.; Schroeder, M. C.; Cody, D. M. R.; Pavia, M. R. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6909-6913.
41. Boojamra, C. G.; Burow, K. M.; Ellman, J. A. J. Org. Chem. 1995, 60, 5742-5743.
42. Goff, D. A.; Zuckermann, R. N. J. Org. Chem. 1995, 60, 5744-5745.
43. Moroder, L.; Lutz, J.; Grams, F.; Rudolph-Böhner, S.; Ösapay, G.; Goodman, M.; Kolbeck, W. Biopolymers 1996, 38, 295-300.
44. Cho, N. S.; Song, K. Y.; Párkanyi, C. J. Heterocycl. Chem. 1989, 26, 1807-1810.
45. Hoffmann, E.; Jagnicinski, B. J. Heterocycl. Chem. 1966, 3, 348-351.
46. Carabateas, P. M.; Harris, L. S. J. Med. Chem. 1966, 9, 6-10.
47. Carabateas, P. M. U.S. Patent 3 415 814, 1968.
48. Carabateas, P. M. U.S. Patent 3 384 635, 1968.
49. Uskokovic, M.; lacobelli, J.; Wenner, W. J. Org. Chem. 1962, 27, 3606-3608.
50. Uskokovic, M. R., Wenner, W. U.S. Patent 3 261 828, 1966.
51. Akssira, M.; Boumzebra, M.; Kasmi, H.; Dahdouh, A.; Roumestant, M. L.; Viallefont, P. Tetrahedron 1994, 50, 9051-9060.
52. Akssira, M.; Kasmi, H.; Dahdouh, A.; Boumzebra, M. Tetrahedron Lett. 1992, 33, 1887-1888.
53. Akssira, M.; Boumzebra, M.; Kasmi, H.; Dahdouh, A.; Roumestant, M. L.; Viallefont, P. Synth. Commun. 1993, 23, 2265-2272.
54. Yamamoto, H.; Inaba, S.; Nakao, M.; Maruyama, I. Chem. Pharm. Bull. 1969, 17, 400-403.
55. Lee, C.-M. J. Heterocycl. Chem. 1964, 1, 235-238.
56. Ishikura, M.; Mori, M.; Ikeda, T.; Terashima, M.; Ban, Y. J. Org. Chem. 1982, 47, 2456-2461.
57. Mori, M.; Ishikura, M.; Ikeda, T.; Ban, Y. Heterocycles 1981, 16, 1491-1494.
58. Mori, M.; Purvaneckas, G. E.; Ishikura, M.; Ban, Y. Chem. Pharm. Bull. 1984, 32, 3840-3847.
59. Mori, M.; Kimura, M.; Uozumi, Y.; Ban, Y. Tetrahedron Lett. 1985, 26, 5947-5950.
60. Eguchi, S.; Yamashita, K.; Matsushita, Y. Synlett 1992, 295-296.
61. Structure searches were performed using the Available Chemicals Directory (ACD), MDL Information Systems, Inc., 14600 Catalina St., San Leandro, CA 94577.
62. Cavelier-Frontin, F.; Pèpe, G.; Verducci, J.; Siri, D.; Jacquier, R. J. Am. Chem. Soc. 1992, 114, 8885-8890.
63. Dale, J.; Titlestad, K. J. Chem. Soc., Chem. Commun. 1969, 656-659.
64. Pastuszak, J.; Gardner, J. H.; Singh, J.; Rich, D. H. J. Org. Chem. 1982, 47, 2982-2987.
65. Steiner, J. R.; Barnes, C. L. Int. J. Pept. Protein Res. 1988, 31, 212-219.
66. Titlestad, K. Acto Chem. Scand., B 1977, 31, 641-661.
67. Jacquier, R.; Lazaro, R.; Raniriseheno, H.; Viallefont, P. Int. J. Pept. Protein Res. 1987, 30, 22-32.
68. Cavelier-Frontin, F.; Achmad, S.; Verducci, J.; Jacquier, R.; Pèpe, G. THEOCHEM 1993, 286, 125-130.
69. Stewart, W. E.; T. H. Siddall, I. Chem. Rev. 1970, 70, 517-551.
70. Vitoux, B.; Aubry, A.; Cung, M. T.; Marraud, M. Int. J. Pept. Protein Res. 1986, 27, 617-632.
71. Landi, J. J.; Ramig, K. Synth. Commun. 1991, 21, 167-171.
72. In initial studies, a monomethoxy analog of the dimethoxy linker described herein was initially employed. However, at the end of the synthesis treatment with TFA resulted in release of the linker from the support still covalently bound to the benzodiazepine.
73. Carpino, L. A.; Elfaham, A.; Albericio, F. Tetrahedron Lett. 1994, 35, 2279-2282.
74. Bordwell, F. G. Acc. Chem. Res. 1988, 21, 456-463.
75. Pirkle, W. H.; Tsipouras, A. J. Chromatogr. 1984, 291, 291-298.
76. Benoiton, N. L. Quantitation and Sequence Dependence of Racemization in Peptide Synthesis. In The Peptides; Gross, E.; Meienhofer, J., Eds.; Academic: New York, 1983; Vol. 5, pp 221-222.
77. König, W.; Geiger, R. Chem. Ber. 1970, 703, 2041-2051.
78. In preliminary studies, good yields of l,4-benzodazepine-2,5-diones incorporating serine were obtained by performing the cyclization with pyridinium hydrochloride in DMF at 90 °C for 48 h. However, the trifluoroacetic acid-mediated cleavage step resulted in significant trifluoroacetylation of the primary hydroxyl. We have not previously observed trifluoroacetylation of secondary alcohols or phenols during the cleavage step. Benzodiazepines incorporating phenylalanine and glycine were also prepared in good yield using these modified cyclization conditions.
79. Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2481.
80. Backes, B. J.; Ellman, J. A. J. Am. Chem. Soc. 1994, 116, 11171-11172.
81. Frenette, R.; Friesen, R. W. Tetrahedron Lett. 1994, 35, 9177-9180.
82. Johnson, C. R.; Braun, M. P. J. Am. Chem. Soc. 1993, 115, 11014-11015.
83. Dewitt, S. H.; Kiely, J. S.; Stankovic, C. J.; Schroeder, M. C.; Cody, D. M. R.; Pavia, M. R. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6909-6913.
84. Geysen, H. M.; Meloen, R. H.; Barteling, S. J. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3998-4002.
85. Meyers, H. V.; Dilley, G. J.; Durgin, T. L.; Powers, T. S:, Winssinger, N. A.; Zhu, H.; Pavia, M. R. Mol. Diversity 1995, 1, 13-20.
86. Valerio, R. M.; Bray, A. M.; Maeji, N. J. Int. J. Pept. Protein Res. 1994, 44, 158-165.
87. Geysen, H. M.; Rodda, S. J.; Mason, T. J.; Tribbick, G.; Schoofs, P. G. J. Immun. Methods 1987, 102, 259.
88. Maeji, N. J.; Bray, A. M.; Valerio, R. M.; Wang, W. Peptide Res. 1995, 8, 33-38.
89. Virgilio, A. A.; Schurer, S.; Ellman, J. A. Tetrahedron, in press.
90. Zuckermann, R. N.; Kerr, J. M.; Siani, M. A.; Banville, S. C. Int. J. Pept. Protein. Res. 1992, 40, 497-506.
91. Glutamine-containing benzodiazepines were not evaluated since they were contaminated with the dimethoxybenzhyrol cleavage side Product.
92. Ullman, F.; Dootson, P. Ber. Dtsch. Chem. Ges. 1918, 51, 9-24.
93. Leggate, P.; Dunn, G. E. Can. J. Chem. 1965, 43, 1158-1174.
94. Landi, J. J.; Ramig, K. Synth. Commun. 1991, 21, 167-171.
95. Gilman, N. W.; Rosen, P.; Early, J. V.; Cook, C.; Todaro, L. J. J. Am. Chem. Soc. 1990, 112, 3969-3978.
96. Gilman, N. W.; Rosen, P.; Earley, J. V.; Cook, C. M.; Blount, J. F.; Todaro, L. J. J. Org. Chem. 1993, 58, 3285-3298.
97. Kovács, J. In The Peptides; Gross, E., Meienhofer, J., Eds.; Academic: New York, 1980; Vol. 2, pp 485-539.